Sign In | Join Free | My
Guangzhou Huao Chemical Co.,Ltd
Guangzhou Huao Chemical Co.,Ltd Legit Steroid Powders , Pre Made Steroids , Peptides , SARM Powder and Pharmaceutical Raw Materials China Reliable Supplier .
Home > Anti Estrogen Steroids >

CAS 129453-61-8 C32H47F5O3S Anti Estrogen Steroid Fulvestrant Powder

CAS 129453-61-8 C32H47F5O3S Anti Estrogen Steroid Fulvestrant Powder

Brand Name : Guangzhou Huao
Model Number : 129453-61-8
Certification : IOS9001 ,Kosher, COA,SGS,USP
Place of Origin : Guangzhou China
MOQ : 10g
Price : Negotiation
Payment Terms : T/T, Western Union,Paypal, MoneyGram,Bitcoin,Bank Transfer
Supply Ability : 1000kg/month
Delivery Time : 4-7 days
Packaging Details : Foil Bag or Tin, Perfect Discreet, as Required
Assay : >99%
transport packing : Foil Bag or Tin, Perfect Discreet, as Required
Reship Policy : Reship Free
samples : Available
Appearance : white crystalline powder
E-mail :
Whatsapp : +8615622635381
Market : Global
Contact Now
Anti Estrogen Steroids Fulvestrant Powder For Breast Cancer
Molecular formulaC32H47F5O3S
The molecular weight606.77

Fulvestrant As Breast cancer treatment drugs

Fulvestrant is an intramuscular drug AstraZeneca R & D, in April 2002 the United States Food and Drug Administration approved for the treatment of anti estrogen therapy after menopause suffering from disease is still getting worse after women with estrogen receptor positive metastatic breast cancer. Estrogen receptors (ER) are found in many breast cancer cells, and estrogen can stimulate the growth of such tumors. Fulvestrant is a pure estrogen receptor antagonist, not estrogen agonist effects, which, through a combination of blocking and down-regulation of ER and inhibit the estrogen signaling pathway that could compete with ER for binding, and the affinity of ER to estrogen, tamoxifen is 100 times, is the only one in tamoxifen after the failure can be widely used for clinical anti estrogen drugs, because the drug for endocrine therapy, will not cause the common adverse reaction of chemotherapy, the patients with good compliance. A number of clinical studies have found that the group 250mg dose has good efficacy in the second-line treatment of advanced breast cancer and is safe and stable.

Mechanism of action
Fulvestrant is a steroid anti estrogen drugs, and its chemical structure is similar to estradiol, the difference is that it has a connection group in the 7 alpha; it is alkyl amine analogues of 17 beta estradiol, by occupying the ER antiestrogen role, and thus inhibit estrogen stimulated gene activation. The effects of estrogen related process necessary for cell cycle; its affinity to ER is 100 times closer to estrogen, tamoxifen. Apoptosis is essential in maintaining homeostasis, and it may also be another major mechanism for the therapeutic effect of this group.

Estrogen receptor antagonist
AstraZeneca, a breast cancer drug, is a small estrogen receptor antagonist that appears to be a major breakthrough in the treatment of breast cancer. Studies show that bone cells have typical estrogen receptors (ERs), while low estrogen levels can lead to bone resorption and osteoporosis. Although the group has a pure antagonistic activity, studies in ovariectomized rats show that it does not have an estrogenic or estrogenic effect, whereas tamoxifen has an estrogen like effect and reduces periosteal formation. Besides, it also has obvious activity in some target organs except mammary gland tissue. On the endometrium, tamoxifen has partial agonist activity, will lead to increased incidence of endometrial cancer, and animal experiment of fulvestrant without the adverse reaction, it not only showed a lack of uterine activity, also can be blocked by tamoxifen on ovariectomy and estrogen treated monkeys received a promotion the mitogenic effect.

Adverse reaction
There were fewer side effects, such as transient vaginal bleeding, changes in taste, and sleepwalking. But there were no signs of facial flushing and sweating, such as vaginal dryness, weight gain, abnormal blood coagulation, thrombosis, and changes in libido. Show a small phase III clinical trial, 19 women with metastatic breast cancer using this product, the clinical effective rate was 67%, no serious security problems, but must continue monthly injection, well tolerated, only slight swelling pain at the injection site, the subjects of the facial flushing and the thickness of endometrium and the levels of sex hormone binding globulin, follicle without any change of hormone and luteinizing hormone levels

Product Tags:

estrogen blocking supplements


estrogen suppression supplements

China Customized Inflatable Bumper Ball Game Bubble Adult Grass CE supplier

CAS 129453-61-8 C32H47F5O3S Anti Estrogen Steroid Fulvestrant Powder Images

Inquiry Cart 0
Inquiry Cart 0